Record-Breaking 323 Medications in Active Shortage in US, ASHP Reports
Drug shortages, US, Record-high, American Society of Health-System Pharmacists (ASHP), 323 medications, Active shortages, Generic sterile injectable medications, Cancer chemotherapy drugs, ADHD medications, Adderall, Drug Enforcement Administration (DEA), Drug supply chains, Policy recommendations
Vertex Acquires Alpine Immune Sciences for $4.9 Billion to Boost Immunology Trail
Vertex Pharmaceuticals, Alpine Immune Sciences, $4.9 billion acquisition, Immunology trail
Novartis Secures $1B Protein Degrader Deal with Arvinas and Initiates MorphoSys Tender Offer
Novartis, Arvinas, Protein Degrader Deal, PROTAC® Androgen Receptor Degrader, MorphoSys Tender Offer
US Drug Shortages Hit Record High Since 2001: ASHP Report
Drug shortages, Record high, American Society of Health-System Pharmacists (ASHP), 323 drugs in shortage, Chemotherapy drugs, ADHD therapies, Central nervous system stimulants, Antimicrobials, Hormone agents, Intravenous fluids, Drug Enforcement Administration (DEA), Biden administration, White House Council on Supply Chain Resilience, Defense Production Act (DPA), Incentives for hospitals, Quality concerns, Controlled substances
Novartis Announces 680 Layoffs in Development Group Amid Corporate Restructuring
Novartis, Layoffs, Development Group, Corporate Restructuring, 680 Jobs, Switzerland, United States, Pharmaceutical Industry
Bristol Myers-backed TORL Raises $158M to Advance Antibody-Drug Conjugates (ADCs) in Clinical Trials
Bristol Myers Squibb, TORL, $158M funding, Antibody-Drug Conjugates (ADCs), Clinical Trials
EMA Dispels Link Between GLP-1 Receptor Agonists and Suicidal Ideation Risk New
EMA, GLP-1 receptor agonists, Diabetes and weight-loss drugs, Suicidal ideation risk, No causal association, Pharmacovigilance activities, Continued monitoring
FDA Approves BrainStorm’s Phase IIIb Trial Design for NurOwn in Early-Stage ALS
BrainStorm Cell Therapeutics, NurOwn, Phase IIIb trial, Special Protocol Assessment (SPA), FDA agreement, Early-stage ALS, Amyotrophic Lateral Sclerosis (ALS)
FDA Oncology Chief Emphasizes Equitable Standards in Confirmatory Trial Rejections at AACR24
AACR24, FDA Oncology Chief, Richard Pazdur, Confirmatory Trial Rejection, Level Playing Field, Project
AstraZeneca and Daiichi Sankyo’s Enhertu Wins Historic FDA Approval as First Tumor-Agnostic HER2-Directed Therapy
Enhertu, AstraZeneca, Daiichi Sankyo, FDA Approval, Tumor-Agnostic, HER2-Directed Therapy, Metastatic HER2-Positive Solid Tumors, Accelerated Approval, DESTINY-PanTumor02 Study, Objective Response Rate (ORR), Duration of Response (DoR)